NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant
- 31 October 1994
- journal article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 105 (1), 1-10
- https://doi.org/10.1016/0303-7207(94)90029-9
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Growth factor signaling by receptor tyrosine kinasesNeuron, 1992
- Isolation of the NeuHER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cellsCell, 1992
- Signal transduction by receptors with tyrosine kinase activityCell, 1990
- Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogeneCell, 1989
- Neu receptor dimerizationNature, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucoseCell, 1986
- Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptorNature, 1986
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985